Latest Regulatory Filings News

CZR Resources has extended gold mineralisation at Croydon, including its strongest Top Camp result to date, while high-grade iron sampling adds momentum across its Pilbara portfolio. But the company’s proposed Zuleika Gold takeover has run into a shareholder approval failure and now requires ASIC consent to be withdrawn.

Critica has put a combined after-tax NPV of about A$3.0 billion across its Mt Lindsay and Jupiter projects, but ended September with just A$3.3 million in cash. Both developments remain at scoping-study stage and require substantial funding that has not yet been secured.

Metal Powder Works has secured its first multi-year order, lifting backlog to approximately A$1.3 million and bringing forward its 800-tonne annual capacity target. The commercial progress comes with a sharper funding question, as quarterly operating cash outflow reached A$3.3 million against A$6.9 million of cash.

Terra Critical Minerals has secured formal access to Glen Eden Station in NSW, clearing a 30-year land access barrier ahead of planned tungsten drilling. The explorer ended September with A$274,000 in cash and an estimated four quarters of funding at its current spending rate, before the cost of drilling is considered.

OMG Group has confirmed its first positive quarterly EBITDA, with Q1 FY27 sales rising 59% to approximately $1.92 million and gross profit growing faster than revenue. The result marks an earnings milestone, but operating cash flow remained negative as the company invested heavily in inventory and supplier deposits.

HITIQ has expanded its military research ambitions and added fresh funding during the September quarter, but the company ended the period with $658,242 in cash and estimated funding for only one quarter. Its US collaboration remains non-binding, leaving financing and commercial execution as the immediate tests.

Macallum New Energy has expanded its Perth Basin exploration inventory, secured commitments for an approximately A$3 million placement and begun seeking a partner to help fund up to two wells in late 2027. The immediate constraint is clear: cash stood at A$0.815 million at quarter-end, equivalent to only 0.8 quarters of funding before the raise.

Decidr AI Industries reported a sharp quarterly fall in its invoicing-based AER, even as customer receipts reached a record and Sugarwork’s qualified pipeline expanded. The company is relying on A$11 million of annualised cost reductions and upcoming product launches to extend its runway and convert enterprise interest into recurring revenue.

Ceretas has enrolled the first patient in its Phase 2 CERE-CALM Alzheimer’s trial after completing its first quarter as an ASX-listed company. The medical technology group ended September with $7.1 million in cash, while a device milestone unlocked a further $692,578 in non-dilutive funding.

Burley Minerals has confirmed shallow Channel Iron Deposit mineralisation across its Cane Bore North and Step-Out Targets, with assays reaching 52.7% iron. The exploration success comes alongside $725,000 in cash and an estimated 2.04 quarters of funding at current outgoings.

OncoSil Medical enters FY27 with FDA approval for its cancer device, rising quarterly revenue and fresh institutional funding, but its U.S. opportunity still depends on reimbursement and a tightly controlled initial rollout. Cash rose to A$8.7 million after the capital raise, while operating cash use remained substantial.

Bio-Gene Technology has moved closer to two commercialisation milestones, with Qcide product work progressing in Japan and a first Flavocide regulatory submission targeted for Q2 2027. The company ended September with A$2.103 million in cash, equivalent to an estimated 2.18 quarters of funding at the quarter’s operating cash rate.